Health Care [ 7/12 ] | Biotechnology [ 35/73 ]
NASDAQ | Common Stock
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients.
It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC).
The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma.
In addition, it develops the"enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors.
The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020.
Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 25 | -0.14 Increased by +51.35% | -0.24 Increased by +42.92% |
| Mar 14, 25 | -0.23 Increased by +39.03% | -0.23 Decreased by -0.65% |
| Nov 14, 24 | -0.33 Decreased by -7.26% | - |
| Aug 13, 24 | -0.74 Decreased by -118.91% | - |
| May 14, 24 | -0.28 Increased by +6.13% | - |
| Mar 28, 24 | -0.38 Decreased by -111.11% | -0.16 Decreased by -137.50% |
| Nov 9, 23 | -0.31 Decreased by -3.33% | -0.19 Decreased by -63.16% |
| Aug 10, 23 | -0.34 Decreased by -6.25% | -0.30 Decreased by -13.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by -100.00% | 7.38 M Increased by +189.76% | Increased by +N/A% Increased by +N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -14.07 M Decreased by -26.84% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -10.65 M Decreased by -26.21% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -22.24 M Decreased by -131.30% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 1.78 M Increased by +N/A% | -8.22 M Increased by +6.53% | Decreased by -462.89% Decreased by N/A% |
| Dec 31, 23 | 1.78 M Increased by +5.63 K% | -11.10 M Decreased by -204.16% | Decreased by -624.72% Decreased by -101.82% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -8.44 M Increased by +0.71% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -9.61 M Decreased by -2.21 K% | Decreased by N/A% Decreased by N/A% |